RHYTHM PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
| | |
| Item 9B. | Other Information |
|---|
a)Disclosure in lieu of reporting on a Current Report on Form 8-K.
None.
b)Insider Trading Arrangements and Policies.
On December 13, 2024, Yann Mazabraud, the Company’s EVP, Head of International, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 99,495 shares of the Company’s common stock until November 11, 2025.
On December 16, 2024, Pamela Cramer, the Company’s Chief Human Resources Officer, terminated a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, originally adopted on May 10, 2024, for the sale of up to 98,937 shares of the Company’s common stock, originally set to expire on May 15, 2025.
On December 16, 2024, Pamela Cramer, the Company’s Chief Human Resources Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 50,394 shares of the Company’s common stock until March 17, 2026.
Other than as disclosed above, during the three months ended December 31, 2024, no director or officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.